Expert Commentary

What is the ideal treatment timing for bisphosphonate therapy?

OBG Manag. 2017 November;29(11)
By
John T. Repke, MD
Author and Disclosure Information

WHAT DOES THIS MEAN FOR PRACTICE?

  • Oral bisphosphonates remain in our armamentarium for reducing fracture in postmenopausal patients

  • Ideal duration of therapy remains unclear

  • Counsel patients: up to 2 y of therapy reduces fracture risk; >10 y of therapy may increase fracture risk


 

Citation: Drieling RL, LaCroix AZ, Beresford SA, et al. Long-term oral bisphosphonate therapy and fractures in older women: the Women’s Health Initiative. J Am Geriatr Soc. 2017;65(9):1924-1931.

Recommended Reading

VIDEO: Dr. Andrew Kaunitz’s top lessons from NAMS 2017
MDedge ObGyn
VIDEO: New sexual desire drugs coming for women
MDedge ObGyn
VIDEO: Expert roundtable on hormone therapy
MDedge ObGyn
Flu shots and persuasion
MDedge ObGyn
Two Senators reach deal on a health law fix
MDedge ObGyn
Clinical pearls from NAMS 2017
MDedge ObGyn
Over 40% of Americans have experience with medical errors
MDedge ObGyn
Does newly discovered vasoactive peptide ELABELA reveal essential mechanisms for preeclampsia development?
MDedge ObGyn
CDC: Zika-exposed newborns need intensified eye, hearing, and neurological testing
MDedge ObGyn
“I’m sorry, doctor, I’m afraid I can’t do that”
MDedge ObGyn